Arbutus Biopharma Corp 8-K

What Happened
Arbutus Biopharma Corporation announced its financial results for the fourth quarter and the year ended December 31, 2025. The company furnished a press release dated March 23, 2026 as Exhibit 99.1 to an SEC Form 8-K (Item 2.02) filed the same day; the release is incorporated by reference in the filing.

Key Details

• Filing date: March 23, 2026 (Form 8-K).
• Reported period: fourth quarter and full year ended December 31, 2025.
• Press release: dated March 23, 2026 and furnished as Exhibit 99.1 to the 8-K.
• Administrative items: Interactive XBRL data embedded; Form 8-K signed by CFO Tuan Nguyen.

Why It Matters
Earnings releases update investors on recent revenue, expenses, and cash position trends that can affect valuation and near-term expectations. This 8-K signals that Arbutus has publicly reported its Q4 and full-year 2025 results; investors should review the March 23, 2026 press release (Exhibit 99.1) and any accompanying financial statements or filings for the specific figures and management commentary before making investment decisions.